What is Jazz Pharmaceuticals Plc's earnings per share (EPS)?

Jazz Pharmaceuticals Plc (JAZZ) reported diluted earnings per share of $-5.84 for fiscal year 2025. This represents a -167.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jazz Pharmaceuticals Plc Financials

JAZZ

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Jazz Pharmaceuticals Plc (JAZZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 43/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Jazz Pharmaceuticals Plc has an operating margin of -10.1%, meaning the company retains $-10 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 17.6% the prior year.

Growth

Jazz Pharmaceuticals Plc's revenue grew a modest 4.9% year-over-year to $4.3B. This slow but positive growth earns a score of 41/100.

Leverage

Jazz Pharmaceuticals Plc carries a low D/E ratio of 1.00, meaning only $1.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 82/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Jazz Pharmaceuticals Plc's current ratio of 1.86 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

100

Jazz Pharmaceuticals Plc converts 30.4% of revenue into free cash flow ($1.3B). This strong cash generation earns a score of 100/100.

Returns

Jazz Pharmaceuticals Plc generates a -8.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 13.7% the prior year.

Piotroski F-Score Neutral

4/9

Jazz Pharmaceuticals Plc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-3.81x

For every $1 of reported earnings, Jazz Pharmaceuticals Plc generates $-3.81 in operating cash flow ($1.4B OCF vs -$356.1M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.3B

YoY+4.9%

5Y CAGR+12.5%

10Y CAGR+12.4%

Jazz Pharmaceuticals Plc generated $4.3B in revenue in fiscal year 2025. This represents an increase of 4.9% from the prior year.

EBITDA

-$388.6M

YoY-151.9%

Jazz Pharmaceuticals Plc's EBITDA was -$388.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 151.9% from the prior year.

Net Income

-$356.1M

YoY-163.6%

Jazz Pharmaceuticals Plc reported -$356.1M in net income in fiscal year 2025. This represents a decrease of 163.6% from the prior year.

EPS (Diluted)

$-5.84

YoY-167.5%

Jazz Pharmaceuticals Plc earned $-5.84 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 167.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.3B

YoY-4.5%

5Y CAGR+8.0%

10Y CAGR+10.1%

Jazz Pharmaceuticals Plc generated $1.3B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 4.5% from the prior year.

Cash & Debt

$1.4B

YoY-42.3%

5Y CAGR+5.6%

10Y CAGR+3.5%

Jazz Pharmaceuticals Plc held $1.4B in cash against $4.3B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

61M

YoY+1.3%

5Y CAGR+1.8%

10Y CAGR+0.0%

Jazz Pharmaceuticals Plc had 61M shares outstanding in fiscal year 2025. This represents an increase of 1.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-10.1%

YoY-27.7pp

5Y CAGR-26.1pp

10Y CAGR-48.4pp

Jazz Pharmaceuticals Plc's operating margin was -10.1% in fiscal year 2025, reflecting core business profitability. This is down 27.7 percentage points from the prior year.

Net Margin

-8.3%

YoY-22.1pp

5Y CAGR-18.4pp

10Y CAGR-33.2pp

Jazz Pharmaceuticals Plc's net profit margin was -8.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 22.1 percentage points from the prior year.

Return on Equity

-8.3%

YoY-21.9pp

5Y CAGR-14.8pp

10Y CAGR-27.6pp

Jazz Pharmaceuticals Plc's ROE was -8.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 21.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$782.7M

YoY-11.5%

5Y CAGR+18.5%

10Y CAGR+19.2%

Jazz Pharmaceuticals Plc invested $782.7M in research and development in fiscal year 2025. This represents a decrease of 11.5% from the prior year.

Share Buybacks

$125.0M

YoY-59.9%

5Y CAGR-3.1%

10Y CAGR+7.3%

Jazz Pharmaceuticals Plc spent $125.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 59.9% from the prior year.

Capital Expenditures

$58.8M

YoY+54.3%

5Y CAGR+31.4%

10Y CAGR+5.0%

Jazz Pharmaceuticals Plc invested $58.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.3% from the prior year.

JAZZ Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.3B+4.9%	$4.1B+6.1%	$3.8B+4.8%	$3.7B+18.3%	$3.1B+30.9%	$2.4B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$782.7M-11.5%	$884.0M+4.0%	$849.7M+43.9%	$590.5M+16.7%	$505.7M+50.8%	$335.4M
SG&A Expenses	$1.8B+30.6%	$1.4B+3.1%	$1.3B-5.2%	$1.4B-2.4%	$1.5B+69.9%	$854.2M
Operating Income	-$430.2M-160.0%	$716.6M+23.9%	$578.6M+983.0%	-$65.5M-138.5%	$170.3M-55.0%	$378.1M
Interest Expense	N/A	N/A	$32.8M0.0%	$32.8M-63.5%	$89.9M+2.6%	$87.6M
Income Tax	-$272.4M-198.0%	-$91.4M+23.8%	-$119.9M+24.4%	-$158.6M-173.4%	$216.1M+544.8%	$33.5M
Net Income	-$356.1M-163.6%	$560.1M+35.0%	$414.8M+285.1%	-$224.1M+32.0%	-$329.7M-238.2%	$238.6M
EPS (Diluted)	$-5.84-167.5%	$8.65+41.8%	$6.10+270.4%	$-3.58+35.1%	$-5.52-230.8%	$4.22

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.2B+6.4%	$1.1B+7.7%	$1.0B+16.5%	$897.8M-17.5%	$1.1B+3.1%	$1.1B+3.0%	$1.0B+13.5%	$902.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$213.9M+7.9%	$198.2M+4.3%	$190.0M+5.2%	$180.7M-24.9%	$240.5M+20.3%	$199.9M-9.4%	$220.7M-0.9%	$222.8M
SG&A Expenses	$406.2M-23.4%	$530.6M+48.1%	$358.4M-30.3%	$514.0M+39.2%	$369.3M+13.4%	$325.8M-3.8%	$338.5M-3.7%	$351.7M
Operating Income	$254.5M+342.6%	$57.5M+108.4%	-$686.4M-1128.1%	-$55.9M-129.3%	$190.8M-26.7%	$260.2M+30.5%	$199.4M+201.2%	$66.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$5.0M+102.0%	-$242.4M-1311.9%	-$17.2M+3.6%	-$17.8M+69.2%	-$57.9M-298.5%	-$14.5M+52.6%	-$30.7M-362.7%	$11.7M
Net Income	$203.5M-19.1%	$251.4M+135.0%	-$718.5M-676.4%	-$92.5M-148.4%	$191.1M-11.1%	$215.1M+27.6%	$168.6M+1253.2%	-$14.6M
EPS (Diluted)	N/A	$4.08+134.8%	$-11.74-672.4%	$-1.52	N/A	$3.42+37.3%	$2.49+1182.6%	$-0.23

JAZZ Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$11.7B-2.9%	$12.0B+5.4%	$11.4B+5.2%	$10.8B-11.9%	$12.3B+88.2%	$6.5B
Current Assets	$4.2B-10.0%	$4.6B+34.7%	$3.4B+31.8%	$2.6B-0.2%	$2.6B-8.0%	$2.8B
Cash & Equivalents	$1.4B-42.3%	$2.4B+60.2%	$1.5B+70.9%	$881.5M+49.0%	$591.4M-44.1%	$1.1B
Inventory	$417.0M-13.2%	$480.4M-19.5%	$597.0M-16.4%	$714.1M-33.4%	$1.1B+1024.5%	$95.4M
Accounts Receivable	$830.7M+15.9%	$716.8M+1.6%	$705.8M+8.3%	$651.5M+15.6%	$563.4M+42.1%	$396.5M
Goodwill	$1.8B+6.6%	$1.7B-2.1%	$1.8B+3.6%	$1.7B-7.4%	$1.8B+90.7%	$958.3M
Total Liabilities	$7.3B-7.3%	$7.9B+3.4%	$7.7B-1.2%	$7.7B-7.0%	$8.3B+189.7%	$2.9B
Current Liabilities	$2.2B+115.9%	$1.0B-32.4%	$1.5B+64.7%	$933.2M+15.3%	$809.3M+23.8%	$653.7M
Long-Term Debt	$4.3B-28.8%	$6.1B+19.0%	$5.1B-10.3%	$5.7B-5.4%	$6.0B+225.6%	$1.8B
Total Equity	$4.3B+5.5%	$4.1B+9.5%	$3.7B+21.1%	$3.1B-22.2%	$4.0B+8.3%	$3.7B
Retained Earnings	$646.2M-42.7%	$1.1B+28.3%	$878.7M+19.8%	$733.6M-11.6%	$830.2M-28.4%	$1.2B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$11.7B+2.7%	$11.4B+3.8%	$10.9B-5.1%	$11.5B-4.0%	$12.0B-2.0%	$12.3B+7.9%	$11.4B+0.3%	$11.3B
Current Assets	$4.2B+10.9%	$3.8B+12.1%	$3.4B-18.8%	$4.1B-10.8%	$4.6B+5.4%	$4.4B+19.3%	$3.7B+4.0%	$3.5B
Cash & Equivalents	$1.4B+5.0%	$1.3B+11.4%	$1.2B-36.1%	$1.9B-22.8%	$2.4B+8.8%	$2.2B+63.6%	$1.4B-6.1%	$1.4B
Inventory	$417.0M-13.7%	$483.1M-4.3%	$505.0M+2.5%	$492.8M+2.6%	$480.4M-10.9%	$539.3M-0.6%	$542.6M-6.0%	$577.3M
Accounts Receivable	$830.7M+8.7%	$764.4M+7.1%	$714.0M+9.3%	$653.0M-8.9%	$716.8M-0.9%	$723.6M+3.7%	$698.0M-1.3%	$707.1M
Goodwill	$1.8B+0.1%	$1.8B-0.9%	$1.8B+4.8%	$1.8B+2.5%	$1.7B-4.9%	$1.8B+4.0%	$1.7B-0.2%	$1.7B
Total Liabilities	$7.3B-0.8%	$7.4B+2.2%	$7.2B-1.7%	$7.4B-7.1%	$7.9B-2.1%	$8.1B+6.4%	$7.6B-0.4%	$7.6B
Current Liabilities	$2.2B-1.4%	$2.3B+9.8%	$2.1B+69.4%	$1.2B+17.7%	$1.0B+0.8%	$1.0B-33.8%	$1.6B-0.4%	$1.6B
Long-Term Debt	$4.3B-0.1%	$4.3B-0.1%	$4.3B-18.8%	$5.3B-12.2%	$6.1B-0.1%	$6.1B+19.2%	$5.1B-0.1%	$5.1B
Total Equity	$4.3B+9.1%	$4.0B+6.8%	$3.7B-11.2%	$4.2B+2.0%	$4.1B-1.9%	$4.2B+10.9%	$3.8B+1.8%	$3.7B
Retained Earnings	$646.2M+46.0%	$442.7M+131.4%	$191.3M-81.5%	$1.0B-8.2%	$1.1B+20.4%	$936.2M+7.5%	$871.2M+0.8%	$864.0M

JAZZ Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.4B-2.9%	$1.4B+27.8%	$1.1B-14.1%	$1.3B+63.4%	$778.5M-13.5%	$899.6M
Capital Expenditures	$58.8M+54.3%	$38.1M+58.9%	$24.0M-17.5%	$29.0M+5.1%	$27.6M+84.2%	$15.0M
Free Cash Flow	$1.3B-4.5%	$1.4B+27.1%	$1.1B-14.1%	$1.2B+65.5%	$750.9M-15.1%	$884.6M
Investing Cash Flow	-$1.5B-197.1%	-$508.2M-211.7%	-$163.1M+63.5%	-$446.2M+91.4%	-$5.2B-417.2%	-$1.0B
Financing Cash Flow	-$873.4M-4357.1%	$20.5M+106.7%	-$305.3M+42.3%	-$529.5M-113.3%	$4.0B+651.9%	$528.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$125.0M-59.9%	$311.4M+15.4%	$269.8M+499457.4%	$54K	$0-100.0%	$146.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$362.5M-23.6%	$474.6M+434.1%	$88.9M-79.3%	$429.8M+7.8%	$398.6M0.0%	$398.7M+20.3%	$331.4M+24.0%	$267.2M
Capital Expenditures	$16.7M+10.2%	$15.2M+17.0%	$13.0M-6.6%	$13.9M+4.5%	$13.3M+23.2%	$10.8M+52.1%	$7.1M+2.7%	$6.9M
Free Cash Flow	$345.8M-24.7%	$459.4M+505.4%	$75.9M-81.8%	$415.9M+7.9%	$385.3M-0.7%	$388.0M+19.6%	$324.3M+24.6%	$260.3M
Investing Cash Flow	-$372.2M-13.5%	-$327.8M+48.9%	-$641.0M-279.5%	-$168.9M+12.6%	-$193.3M-190.3%	$214.1M+183.3%	-$257.1M+5.4%	-$271.9M
Financing Cash Flow	$75.4M+796.6%	-$10.8M+91.3%	-$124.5M+84.7%	-$813.5M-9730.4%	-$8.3M-103.4%	$246.4M+253.0%	-$161.1M-184.8%	-$56.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0	N/A	N/A	$0-100.0%	$150.0M	N/A	N/A

JAZZ Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-10.1%-27.7pp	17.6%+2.5pp	15.1%+16.9pp	-1.8%-7.3pp	5.5%-10.5pp	16.0%
Net Margin	-8.3%-22.1pp	13.8%+2.9pp	10.8%+16.9pp	-6.1%+4.5pp	-10.7%-20.8pp	10.1%
Return on Equity	-8.3%-21.9pp	13.7%+2.6pp	11.1%+18.4pp	-7.3%+1.0pp	-8.3%-14.8pp	6.5%
Return on Assets	-3.0%-7.7pp	4.7%+1.0pp	3.6%+5.7pp	-2.1%+0.6pp	-2.7%-6.3pp	3.6%
Current Ratio	1.86-2.6	4.46+2.2	2.24-0.6	2.79-0.4	3.23-1.1	4.34
Debt-to-Equity	1.00-0.5	1.48+0.1	1.37-0.5	1.85+0.3	1.52+1.0	0.51
FCF Margin	30.4%-3.0pp	33.4%+5.5pp	27.9%-6.1pp	34.0%+9.7pp	24.3%-13.2pp	37.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	21.3%+16.1pp	5.1%+70.8pp	-65.6%-59.4pp	-6.2%-23.8pp	17.5%-7.1pp	24.7%+5.2pp	19.5%+12.1pp	7.3%
Net Margin	17.0%-5.3pp	22.3%+91.0pp	-68.7%-58.4pp	-10.3%-27.9pp	17.6%-2.8pp	20.4%+3.9pp	16.5%+18.1pp	-1.6%
Return on Equity	4.7%-1.6pp	6.3%+25.7pp	-19.4%-17.2pp	-2.2%-6.9pp	4.7%-0.5pp	5.2%+0.7pp	4.5%+4.9pp	-0.4%
Return on Assets	1.7%-0.5pp	2.2%+8.8pp	-6.6%-5.8pp	-0.8%-2.4pp	1.6%-0.2pp	1.8%+0.3pp	1.5%+1.6pp	-0.1%
Current Ratio	1.86+0.2	1.65+0.0	1.62-1.8	3.38-1.1	4.46+0.2	4.26+1.9	2.37+0.1	2.27
Debt-to-Equity	1.00-0.1	1.09-0.1	1.17-0.1	1.28-0.2	1.48+0.0	1.46+0.1	1.36-0.0	1.38
FCF Margin	28.9%-11.9pp	40.8%+33.5pp	7.3%-39.1pp	46.3%+10.9pp	35.4%-1.4pp	36.8%+5.1pp	31.7%+2.8pp	28.9%

Similar Companies

Blueprint Medicines Corp BPMC

$8.4B

Legend Biotech Corp LEGN

$3.5B

Verona Pharma VRNA

$9.2B

Bio-Techne Corp TECH

$8.3B

Corcept Therapeutics Inc CORT

$4.5B

Frequently Asked Questions

What is Jazz Pharmaceuticals Plc's annual revenue?

Jazz Pharmaceuticals Plc (JAZZ) reported $4.3B in total revenue for fiscal year 2025. This represents a 4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Jazz Pharmaceuticals Plc's revenue growing?

Jazz Pharmaceuticals Plc (JAZZ) revenue grew by 4.9% year-over-year, from $4.1B to $4.3B in fiscal year 2025.

Is Jazz Pharmaceuticals Plc profitable?

No, Jazz Pharmaceuticals Plc (JAZZ) reported a net income of -$356.1M in fiscal year 2025, with a net profit margin of -8.3%.

What is Jazz Pharmaceuticals Plc's EBITDA?

Jazz Pharmaceuticals Plc (JAZZ) had EBITDA of -$388.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Jazz Pharmaceuticals Plc have?

As of fiscal year 2025, Jazz Pharmaceuticals Plc (JAZZ) had $1.4B in cash and equivalents against $4.3B in long-term debt.

What is Jazz Pharmaceuticals Plc's operating margin?

Jazz Pharmaceuticals Plc (JAZZ) had an operating margin of -10.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Jazz Pharmaceuticals Plc's net profit margin?

Jazz Pharmaceuticals Plc (JAZZ) had a net profit margin of -8.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Jazz Pharmaceuticals Plc's return on equity (ROE)?

Jazz Pharmaceuticals Plc (JAZZ) has a return on equity of -8.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Jazz Pharmaceuticals Plc's free cash flow?

Jazz Pharmaceuticals Plc (JAZZ) generated $1.3B in free cash flow during fiscal year 2025. This represents a -4.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Jazz Pharmaceuticals Plc's operating cash flow?

Jazz Pharmaceuticals Plc (JAZZ) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Jazz Pharmaceuticals Plc's total assets?

Jazz Pharmaceuticals Plc (JAZZ) had $11.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Jazz Pharmaceuticals Plc's capital expenditures?

Jazz Pharmaceuticals Plc (JAZZ) invested $58.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Jazz Pharmaceuticals Plc spend on research and development?

Jazz Pharmaceuticals Plc (JAZZ) invested $782.7M in research and development during fiscal year 2025.

Does Jazz Pharmaceuticals Plc buy back shares?

Yes, Jazz Pharmaceuticals Plc (JAZZ) spent $125.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Jazz Pharmaceuticals Plc have outstanding?

Jazz Pharmaceuticals Plc (JAZZ) had 61M shares outstanding as of fiscal year 2025.

What is Jazz Pharmaceuticals Plc's current ratio?

Jazz Pharmaceuticals Plc (JAZZ) had a current ratio of 1.86 as of fiscal year 2025, which is generally considered healthy.

What is Jazz Pharmaceuticals Plc's debt-to-equity ratio?

Jazz Pharmaceuticals Plc (JAZZ) had a debt-to-equity ratio of 1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jazz Pharmaceuticals Plc's return on assets (ROA)?

Jazz Pharmaceuticals Plc (JAZZ) had a return on assets of -3.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jazz Pharmaceuticals Plc's Piotroski F-Score?

Jazz Pharmaceuticals Plc (JAZZ) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jazz Pharmaceuticals Plc's earnings high quality?

Jazz Pharmaceuticals Plc (JAZZ) has an earnings quality ratio of -3.81x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Jazz Pharmaceuticals Plc?

Jazz Pharmaceuticals Plc (JAZZ) scores 43 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.